{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:45:41Z","timestamp":1777934741349,"version":"3.51.4"},"reference-count":14,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:00:00Z","timestamp":1774051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:00:00Z","timestamp":1774051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"abstract":"\n Background<\/jats:title>\n Futibatinib, a novel FGFR inhibitor, is a promising therapy for cancers with FGFR alterations. However, its safety profile remains under investigation. This study evaluates futibatinib-associated adverse events using the FDA Adverse Event Reporting System (FAERS).<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n A retrospective pharmacovigilance analysis was conducted using FAERS data from January 1, 2013, to March 9, 2025. Disproportionality analysis was performed via OpenVigil 2.1, with signals defined by a reporting odds ratio (ROR)\u2009>\u20092.00 and a 95% confidence interval lower bound >1.00. Events with at least two reports were included after deduplication and standardization.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Strong safety signals were identified. Hyperphosphatasemia showed the highest association (ROR 1612.73; 6 events), followed by elevated blood phosphorus (ROR 603.85; 3 events). Dermatologic toxicities, including onycholysis (ROR 520.15) and onychoclasis (ROR 126.20), were also notable.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n These findings highlight the range of adverse events associated with this agent. These events may reflect direct drug effects and individual variability. Further studies are needed to clarify mechanisms and inform clinical management.<\/jats:p>\n <\/jats:sec>","DOI":"10.1177\/10781552261433918","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T14:21:26Z","timestamp":1774102886000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacovigilance analysis of the FGFR inhibitor futibatinib using the FDA adverse event reporting system (FAERS) database"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4080-3030","authenticated-orcid":false,"given":"Connor","family":"Frey","sequence":"first","affiliation":[{"name":"University of British Columbia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,3,21]]},"reference":[{"key":"e_1_3_3_2_2","first-page":"1","article-title":"Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer","volume":"6","author":"Wu F","year":"2021","unstructured":"Wu F, Yang J, Liu J, et al. Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer. Signal Transduct Target Ther 2021; 6: 1\u201335.","journal-title":"Signal Transduct Target Ther"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01558-1"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2020-0334"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02167-9"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-2568"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-2646"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.3390\/antib13030059"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharma3040026"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1139\/cjpp-2025-0065"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.601006"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206834"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.06.018"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.17161\/kjm.vol18.22862"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2017.1323867"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261433918","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552261433918","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261433918","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:32:34Z","timestamp":1777689154000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552261433918"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,21]]},"references-count":14,"alternative-id":["10.1177\/10781552261433918"],"URL":"https:\/\/doi.org\/10.1177\/10781552261433918","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,21]]},"article-number":"10781552261433918"}}